By Adriano Marchese

 

GlaxoSmithKline PLC (GSK.LN) said Monday that has found positive data over a 96-week period from phase 3 study of investigational Fostemsavir in patients with HIV.

ViiV Healthcare, of which GlaxoSmithKline is a majority shareholder, said rates of virologic suppression and immunologic response increased from week 48 to week 96 in a difficult-to-treat population with multi-drug resistant HIV-1.

The study found that at week 96, 60% of patients receiving Fostemsavir as well as optimized background treatments in the randomized cohort achieved virologic suppression--an increase of 6% from week 48 results.

ViiV plans to begin the submission of regulatory applications for Fostemsavir with the U.S. new-drug application later this year.

 

Write to Adriano Marchese at adriano.marchese@dowjones.com

 

(END) Dow Jones Newswires

July 22, 2019 12:37 ET (16:37 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more GSK Charts.